Does the media refer more to BMY or AMGN?

In the previous week, Bristol Myers Squibb had 9 more articles in the media than Amgen. MarketBeat recorded 73 mentions for Bristol Myers Squibb and 64 mentions for Amgen. Bristol Myers Squibb's average media sentiment score of 1.20 beat Amgen's score of 1.19 indicating that Bristol Myers Squibb is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Bristol Myers Squibb 50 Very Positive mention(s) 3 Positive mention(s) 6 Neutral mention(s) 1 Negative mention(s) 2 Very Negative mention(s) Positive Amgen 49 Very Positive mention(s) 5 Positive mention(s) 3 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to BMY or EXEL?

In the previous week, Bristol Myers Squibb had 63 more articles in the media than Exelixis. MarketBeat recorded 73 mentions for Bristol Myers Squibb and 10 mentions for Exelixis. Bristol Myers Squibb's average media sentiment score of 1.20 beat Exelixis' score of 1.07 indicating that Bristol Myers Squibb is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Bristol Myers Squibb 50 Very Positive mention(s) 3 Positive mention(s) 6 Neutral mention(s) 1 Negative mention(s) 2 Very Negative mention(s) Positive Exelixis 5 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to BMY or GILD?

In the previous week, Gilead Sciences had 21 more articles in the media than Bristol Myers Squibb. MarketBeat recorded 94 mentions for Gilead Sciences and 73 mentions for Bristol Myers Squibb. Gilead Sciences' average media sentiment score of 1.23 beat Bristol Myers Squibb's score of 1.20 indicating that Gilead Sciences is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Bristol Myers Squibb 50 Very Positive mention(s) 3 Positive mention(s) 6 Neutral mention(s) 1 Negative mention(s) 2 Very Negative mention(s) Positive Gilead Sciences 68 Very Positive mention(s) 4 Positive mention(s) 7 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to BMY or VRTX?

In the previous week, Bristol Myers Squibb had 22 more articles in the media than Vertex Pharmaceuticals. MarketBeat recorded 73 mentions for Bristol Myers Squibb and 51 mentions for Vertex Pharmaceuticals. Vertex Pharmaceuticals' average media sentiment score of 1.48 beat Bristol Myers Squibb's score of 1.20 indicating that Vertex Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Bristol Myers Squibb 50 Very Positive mention(s) 3 Positive mention(s) 6 Neutral mention(s) 1 Negative mention(s) 2 Very Negative mention(s) Positive Vertex Pharmaceuticals 44 Very Positive mention(s) 2 Positive mention(s) 2 Neutral mention(s) 3 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to ABBV or BMY?

In the previous week, Bristol Myers Squibb had 24 more articles in the media than AbbVie. MarketBeat recorded 73 mentions for Bristol Myers Squibb and 49 mentions for AbbVie. Bristol Myers Squibb's average media sentiment score of 1.20 beat AbbVie's score of 1.13 indicating that Bristol Myers Squibb is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment AbbVie 34 Very Positive mention(s) 5 Positive mention(s) 8 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Positive Bristol Myers Squibb 50 Very Positive mention(s) 3 Positive mention(s) 6 Neutral mention(s) 1 Negative mention(s) 2 Very Negative mention(s) Positive

Bristol Myers Squibb (BMY) Competitors

$66.80 -0.81 (-1.19%)

As of 10:22 AM Eastern

Compare

BMY vs. AMGN, EXEL, GILD, VRTX, and ABBV

Should you buy Bristol Myers Squibb stock or one of its competitors? Bristol Myers Squibb's main competitors and comparable companies include Amgen (AMGN), Exelixis (EXEL), Gilead Sciences (GILD), Vertex Pharmaceuticals (VRTX), and AbbVie (ABBV). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "healthcare" sector.

How does Bristol Myers Squibb compare to Amgen?

Bristol Myers Squibb (NYSE:BMY) and Amgen (NASDAQ:AMGN) are both large-cap healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their media sentiment, profitability, institutional ownership, dividends, risk, earnings, analyst recommendations and valuation.

76.4% of Bristol Myers Squibb shares are owned by institutional investors. Comparatively, 76.5% of Amgen shares are owned by institutional investors. 0.1% of Bristol Myers Squibb shares are owned by insiders. Comparatively, 0.9% of Amgen shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Amgen has a net margin of 22.95% compared to Bristol Myers Squibb's net margin of 18.87%. Amgen's return on equity of 124.14% beat Bristol Myers Squibb's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Bristol Myers Squibb	18.87%	66.90%	14.74%
Amgen	22.95%	124.14%	13.18%

Bristol Myers Squibb has a beta of 0.22, indicating that its stock price is 78% less volatile than the broader market. Comparatively, Amgen has a beta of 0.41, indicating that its stock price is 59% less volatile than the broader market.

Bristol Myers Squibb pays an annual dividend of $2.52 per share and has a dividend yield of 3.8%. Amgen pays an annual dividend of $10.08 per share and has a dividend yield of 2.3%. Bristol Myers Squibb pays out 55.5% of its earnings in the form of a dividend. Amgen pays out 62.6% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years. Bristol Myers Squibb has increased its dividend for 17 consecutive years and Amgen has increased its dividend for 14 consecutive years. Bristol Myers Squibb is clearly the better dividend stock, given its higher yield and longer track record of dividend growth.

Bristol Myers Squibb currently has a consensus price target of $66.06, suggesting a potential downside of 1.12%. Amgen has a consensus price target of $380.43, suggesting a potential downside of 12.64%. Given Bristol Myers Squibb's stronger consensus rating and higher possible upside, equities research analysts plainly believe Bristol Myers Squibb is more favorable than Amgen.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Bristol Myers Squibb	1 Sell rating(s)	10 Hold rating(s)	13 Buy rating(s)	1 Strong Buy rating(s)	2.56
Amgen	3 Sell rating(s)	14 Hold rating(s)	13 Buy rating(s)	1 Strong Buy rating(s)	2.39

Amgen has lower revenue, but higher earnings than Bristol Myers Squibb. Bristol Myers Squibb is trading at a lower price-to-earnings ratio than Amgen, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Bristol Myers Squibb	$48.19B	2.83	$7.05B	$4.54	14.71
Amgen	$38.10B	6.18	$7.71B	$16.09	27.06

In the previous week, Bristol Myers Squibb had 9 more articles in the media than Amgen. MarketBeat recorded 73 mentions for Bristol Myers Squibb and 64 mentions for Amgen. Bristol Myers Squibb's average media sentiment score of 1.20 beat Amgen's score of 1.19 indicating that Bristol Myers Squibb is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Bristol Myers Squibb	50 Very Positive mention(s)	3 Positive mention(s)	6 Neutral mention(s)	1 Negative mention(s)	2 Very Negative mention(s)	Positive
Amgen	49 Very Positive mention(s)	5 Positive mention(s)	3 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Bristol Myers Squibb and Amgen tied by winning 9 of the 18 factors compared between the two stocks.

How does Bristol Myers Squibb compare to Exelixis?

Bristol Myers Squibb (NYSE:BMY) and Exelixis (NASDAQ:EXEL) are both large-cap healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their analyst recommendations, profitability, media sentiment, dividends, risk, valuation, earnings and institutional ownership.

Bristol Myers Squibb presently has a consensus target price of $66.06, suggesting a potential downside of 1.12%. Exelixis has a consensus target price of $50.07, suggesting a potential downside of 7.85%. Given Bristol Myers Squibb's stronger consensus rating and higher possible upside, analysts plainly believe Bristol Myers Squibb is more favorable than Exelixis.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Bristol Myers Squibb	1 Sell rating(s)	10 Hold rating(s)	13 Buy rating(s)	1 Strong Buy rating(s)	2.56
Exelixis	2 Sell rating(s)	11 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.30

Bristol Myers Squibb has a beta of 0.22, indicating that its stock price is 78% less volatile than the broader market. Comparatively, Exelixis has a beta of 0.44, indicating that its stock price is 56% less volatile than the broader market.

Exelixis has a net margin of 35.33% compared to Bristol Myers Squibb's net margin of 18.87%. Bristol Myers Squibb's return on equity of 66.90% beat Exelixis' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Bristol Myers Squibb	18.87%	66.90%	14.74%
Exelixis	35.33%	42.17%	31.76%

76.4% of Bristol Myers Squibb shares are held by institutional investors. Comparatively, 85.3% of Exelixis shares are held by institutional investors. 0.1% of Bristol Myers Squibb shares are held by insiders. Comparatively, 2.6% of Exelixis shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

In the previous week, Bristol Myers Squibb had 63 more articles in the media than Exelixis. MarketBeat recorded 73 mentions for Bristol Myers Squibb and 10 mentions for Exelixis. Bristol Myers Squibb's average media sentiment score of 1.20 beat Exelixis' score of 1.07 indicating that Bristol Myers Squibb is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Bristol Myers Squibb	50 Very Positive mention(s)	3 Positive mention(s)	6 Neutral mention(s)	1 Negative mention(s)	2 Very Negative mention(s)	Positive
Exelixis	5 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Bristol Myers Squibb has higher revenue and earnings than Exelixis. Bristol Myers Squibb is trading at a lower price-to-earnings ratio than Exelixis, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Bristol Myers Squibb	$48.19B	2.83	$7.05B	$4.54	14.71
Exelixis	$2.32B	5.80	$782.57M	$3.18	17.08

Summary

Bristol Myers Squibb beats Exelixis on 9 of the 16 factors compared between the two stocks.

How does Bristol Myers Squibb compare to Gilead Sciences?

Bristol Myers Squibb (NYSE:BMY) and Gilead Sciences (NASDAQ:GILD) are both large-cap healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their valuation, earnings, profitability, media sentiment, dividends, analyst recommendations, risk and institutional ownership.

In the previous week, Gilead Sciences had 21 more articles in the media than Bristol Myers Squibb. MarketBeat recorded 94 mentions for Gilead Sciences and 73 mentions for Bristol Myers Squibb. Gilead Sciences' average media sentiment score of 1.23 beat Bristol Myers Squibb's score of 1.20 indicating that Gilead Sciences is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Bristol Myers Squibb	50 Very Positive mention(s)	3 Positive mention(s)	6 Neutral mention(s)	1 Negative mention(s)	2 Very Negative mention(s)	Positive
Gilead Sciences	68 Very Positive mention(s)	4 Positive mention(s)	7 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Positive

76.4% of Bristol Myers Squibb shares are held by institutional investors. Comparatively, 83.7% of Gilead Sciences shares are held by institutional investors. 0.1% of Bristol Myers Squibb shares are held by company insiders. Comparatively, 0.3% of Gilead Sciences shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Gilead Sciences has lower revenue, but higher earnings than Bristol Myers Squibb. Gilead Sciences is trading at a lower price-to-earnings ratio than Bristol Myers Squibb, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Bristol Myers Squibb	$48.19B	2.83	$7.05B	$4.54	14.71
Gilead Sciences	$30.46B	5.89	$8.51B	-$2.67	N/A

Bristol Myers Squibb has a beta of 0.22, meaning that its share price is 78% less volatile than the broader market. Comparatively, Gilead Sciences has a beta of 0.32, meaning that its share price is 68% less volatile than the broader market.

Bristol Myers Squibb pays an annual dividend of $2.52 per share and has a dividend yield of 3.8%. Gilead Sciences pays an annual dividend of $3.28 per share and has a dividend yield of 2.3%. Bristol Myers Squibb pays out 55.5% of its earnings in the form of a dividend. Gilead Sciences pays out -122.8% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years. Bristol Myers Squibb has increased its dividend for 17 consecutive years and Gilead Sciences has increased its dividend for 10 consecutive years. Bristol Myers Squibb is clearly the better dividend stock, given its higher yield and longer track record of dividend growth.

Bristol Myers Squibb presently has a consensus price target of $66.06, suggesting a potential downside of 1.12%. Gilead Sciences has a consensus price target of $158.04, suggesting a potential upside of 9.20%. Given Gilead Sciences' stronger consensus rating and higher possible upside, analysts plainly believe Gilead Sciences is more favorable than Bristol Myers Squibb.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Bristol Myers Squibb	1 Sell rating(s)	10 Hold rating(s)	13 Buy rating(s)	1 Strong Buy rating(s)	2.56
Gilead Sciences	0 Sell rating(s)	5 Hold rating(s)	24 Buy rating(s)	0 Strong Buy rating(s)	2.83

Bristol Myers Squibb has a net margin of 18.87% compared to Gilead Sciences' net margin of -10.64%. Bristol Myers Squibb's return on equity of 66.90% beat Gilead Sciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Bristol Myers Squibb	18.87%	66.90%	14.74%
Gilead Sciences	-10.64%	-2.11%	-0.75%

Summary

Gilead Sciences beats Bristol Myers Squibb on 11 of the 20 factors compared between the two stocks.

How does Bristol Myers Squibb compare to Vertex Pharmaceuticals?

Bristol Myers Squibb (NYSE:BMY) and Vertex Pharmaceuticals (NASDAQ:VRTX) are both large-cap healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their institutional ownership, risk, valuation, profitability, media sentiment, earnings, analyst recommendations and dividends.

Vertex Pharmaceuticals has a net margin of 35.00% compared to Bristol Myers Squibb's net margin of 18.87%. Bristol Myers Squibb's return on equity of 66.90% beat Vertex Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Bristol Myers Squibb	18.87%	66.90%	14.74%
Vertex Pharmaceuticals	35.00%	23.09%	16.72%

76.4% of Bristol Myers Squibb shares are owned by institutional investors. Comparatively, 91.0% of Vertex Pharmaceuticals shares are owned by institutional investors. 0.1% of Bristol Myers Squibb shares are owned by insiders. Comparatively, 0.2% of Vertex Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

In the previous week, Bristol Myers Squibb had 22 more articles in the media than Vertex Pharmaceuticals. MarketBeat recorded 73 mentions for Bristol Myers Squibb and 51 mentions for Vertex Pharmaceuticals. Vertex Pharmaceuticals' average media sentiment score of 1.48 beat Bristol Myers Squibb's score of 1.20 indicating that Vertex Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Bristol Myers Squibb	50 Very Positive mention(s)	3 Positive mention(s)	6 Neutral mention(s)	1 Negative mention(s)	2 Very Negative mention(s)	Positive
Vertex Pharmaceuticals	44 Very Positive mention(s)	2 Positive mention(s)	2 Neutral mention(s)	3 Negative mention(s)	0 Very Negative mention(s)	Positive

Bristol Myers Squibb has higher revenue and earnings than Vertex Pharmaceuticals. Bristol Myers Squibb is trading at a lower price-to-earnings ratio than Vertex Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Bristol Myers Squibb	$48.19B	2.83	$7.05B	$4.54	14.71
Vertex Pharmaceuticals	$12.00B	11.56	$3.95B	$17.18	31.82

Bristol Myers Squibb currently has a consensus target price of $66.06, suggesting a potential downside of 1.12%. Vertex Pharmaceuticals has a consensus target price of $563.50, suggesting a potential upside of 3.07%. Given Vertex Pharmaceuticals' stronger consensus rating and higher probable upside, analysts clearly believe Vertex Pharmaceuticals is more favorable than Bristol Myers Squibb.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Bristol Myers Squibb	1 Sell rating(s)	10 Hold rating(s)	13 Buy rating(s)	1 Strong Buy rating(s)	2.56
Vertex Pharmaceuticals	0 Sell rating(s)	3 Hold rating(s)	20 Buy rating(s)	1 Strong Buy rating(s)	2.92

Bristol Myers Squibb has a beta of 0.22, meaning that its stock price is 78% less volatile than the broader market. Comparatively, Vertex Pharmaceuticals has a beta of 0.3, meaning that its stock price is 70% less volatile than the broader market.

Summary

Vertex Pharmaceuticals beats Bristol Myers Squibb on 12 of the 16 factors compared between the two stocks.

How does Bristol Myers Squibb compare to AbbVie?

AbbVie (NYSE:ABBV) and Bristol Myers Squibb (NYSE:BMY) are both large-cap healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their profitability, dividends, earnings, risk, media sentiment, valuation, analyst recommendations and institutional ownership.

AbbVie has a beta of 0.3, suggesting that its stock price is 70% less volatile than the broader market. Comparatively, Bristol Myers Squibb has a beta of 0.22, suggesting that its stock price is 78% less volatile than the broader market.

70.2% of AbbVie shares are owned by institutional investors. Comparatively, 76.4% of Bristol Myers Squibb shares are owned by institutional investors. 0.1% of AbbVie shares are owned by company insiders. Comparatively, 0.1% of Bristol Myers Squibb shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Bristol Myers Squibb has lower revenue, but higher earnings than AbbVie. Bristol Myers Squibb is trading at a lower price-to-earnings ratio than AbbVie, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
AbbVie	$64.39B	7.28	$4.23B	$3.54	74.92
Bristol Myers Squibb	$48.19B	2.83	$7.05B	$4.54	14.71

AbbVie currently has a consensus price target of $275.95, indicating a potential upside of 4.05%. Bristol Myers Squibb has a consensus price target of $66.06, indicating a potential downside of 1.12%. Given AbbVie's stronger consensus rating and higher possible upside, equities research analysts plainly believe AbbVie is more favorable than Bristol Myers Squibb.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
AbbVie	0 Sell rating(s)	5 Hold rating(s)	19 Buy rating(s)	2 Strong Buy rating(s)	2.88
Bristol Myers Squibb	1 Sell rating(s)	10 Hold rating(s)	13 Buy rating(s)	1 Strong Buy rating(s)	2.56

Bristol Myers Squibb has a net margin of 18.87% compared to AbbVie's net margin of 9.80%. Bristol Myers Squibb's return on equity of 66.90% beat AbbVie's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
AbbVie	9.80%	-422.07%	14.34%
Bristol Myers Squibb	18.87%	66.90%	14.74%

In the previous week, Bristol Myers Squibb had 24 more articles in the media than AbbVie. MarketBeat recorded 73 mentions for Bristol Myers Squibb and 49 mentions for AbbVie. Bristol Myers Squibb's average media sentiment score of 1.20 beat AbbVie's score of 1.13 indicating that Bristol Myers Squibb is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
AbbVie	34 Very Positive mention(s)	5 Positive mention(s)	8 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Positive
Bristol Myers Squibb	50 Very Positive mention(s)	3 Positive mention(s)	6 Neutral mention(s)	1 Negative mention(s)	2 Very Negative mention(s)	Positive

AbbVie pays an annual dividend of $6.92 per share and has a dividend yield of 2.6%. Bristol Myers Squibb pays an annual dividend of $2.52 per share and has a dividend yield of 3.8%. AbbVie pays out 195.5% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future. Bristol Myers Squibb pays out 55.5% of its earnings in the form of a dividend. AbbVie has increased its dividend for 53 consecutive years and Bristol Myers Squibb has increased its dividend for 17 consecutive years. Bristol Myers Squibb is clearly the better dividend stock, given its higher yield and lower payout ratio.

Summary

AbbVie and Bristol Myers Squibb tied by winning 10 of the 20 factors compared between the two stocks.

Get Bristol Myers Squibb News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding BMY and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

BMY vs. The Competition

Export

Metric	Bristol Myers Squibb	Pharmaceuticals Industry	Healthcare Sector	NYSE Exchange
Market Cap	$136.76B	$12.42B	$7.29B	$24.18B
Dividend Yield	3.82%	2.66%	2.55%	3.72%
P/E Ratio	14.75	777.33	269.25	30.13
Price / Sales	2.83	760.24	615.11	19.89
Price / Cash	8.12	96.52	78.23	31.97
Price / Book	6.11	12.13	13.24	6.84
Net Income	$7.05B	$2.81B	$3.47B	$1.07B
7 Day Performance	3.26%	1.20%	1.85%	-0.90%
1 Month Performance	10.78%	2.72%	4.99%	2.62%
1 Year Performance	38.46%	8.33%	28.36%	17.81%

Bristol Myers Squibb Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
BMY Bristol Myers Squibb	4.2096 of 5 stars	$66.80 -1.2%	$66.06 -1.1%	+39.9%	$136.76B	$48.19B	14.75	32,500	Positive News Analyst Upgrade Options Volume Analyst Revision
AMGN Amgen	3.8644 of 5 stars	$417.84 +0.4%	$371.68 -11.0%	+49.7%	$225.00B	$38.10B	25.97	31,500	Positive News Analyst Forecast
EXEL Exelixis	3.3746 of 5 stars	$50.61 +0.5%	$49.79 -1.6%	+45.0%	$12.48B	$2.32B	15.92	1,077	Positive News Analyst Forecast
GILD Gilead Sciences	4.0966 of 5 stars	$138.14 +1.7%	$158.04 +14.4%	+25.1%	$168.47B	$30.46B	N/A	17,000	Trending News Insider Trade Analyst Revision
VRTX Vertex Pharmaceuticals	4.2372 of 5 stars	$516.44 -1.8%	$563.50 +9.1%	+41.3%	$133.43B	$12.00B	30.06	6,400	Positive News

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NYSE:BMY) was last updated on 8/20/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Bristol Myers Squibb (BMY) Competitors

BMY vs. AMGN, EXEL, GILD, VRTX, and ABBV

How does Bristol Myers Squibb compare to Amgen?

Summary

How does Bristol Myers Squibb compare to Exelixis?

Summary

How does Bristol Myers Squibb compare to Gilead Sciences?

Summary

How does Bristol Myers Squibb compare to Vertex Pharmaceuticals?

Summary

How does Bristol Myers Squibb compare to AbbVie?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

BMY vs. The Competition

Bristol Myers Squibb Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Bristol Myers Squibb (BMY) Competitors

BMY vs. AMGN, EXEL, GILD, VRTX, and ABBV

How does Bristol Myers Squibb compare to Amgen?

Do insiders and institutionals hold more shares of BMY or AMGN?

Is BMY or AMGN more profitable?

Which has more risk and volatility, BMY or AMGN?

Is BMY or AMGN a better dividend stock?

Do analysts recommend BMY or AMGN?

Which has higher valuation & earnings, BMY or AMGN?

Does the media refer more to BMY or AMGN?

Summary

How does Bristol Myers Squibb compare to Exelixis?

Do analysts prefer BMY or EXEL?

Which has more risk and volatility, BMY or EXEL?

Is BMY or EXEL more profitable?

Do insiders & institutionals hold more shares of BMY or EXEL?

Does the media refer more to BMY or EXEL?

Which has higher earnings and valuation, BMY or EXEL?

Summary

How does Bristol Myers Squibb compare to Gilead Sciences?

Does the media refer more to BMY or GILD?

Do insiders and institutionals have more ownership in BMY or GILD?

Which has stronger valuation and earnings, BMY or GILD?

Which has more risk & volatility, BMY or GILD?

Is BMY or GILD a better dividend stock?

Do analysts recommend BMY or GILD?

Is BMY or GILD more profitable?

Summary

How does Bristol Myers Squibb compare to Vertex Pharmaceuticals?

Is BMY or VRTX more profitable?

Do insiders and institutionals hold more shares of BMY or VRTX?

Does the media refer more to BMY or VRTX?

Which has preferable earnings & valuation, BMY or VRTX?

Do analysts rate BMY or VRTX?

Which has more volatility and risk, BMY or VRTX?

Summary

How does Bristol Myers Squibb compare to AbbVie?

Which has more risk & volatility, ABBV or BMY?

Do insiders & institutionals believe in ABBV or BMY?

Which has preferable valuation & earnings, ABBV or BMY?

Do analysts prefer ABBV or BMY?

Is ABBV or BMY more profitable?

Does the media refer more to ABBV or BMY?

Is ABBV or BMY a better dividend stock?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

BMY vs. The Competition

Bristol Myers Squibb Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools